Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17135916 | RXR-ALPHA�GENE�KNOCKOUT�CELL�LINE�WITH�STABLE�AND�LOW�RXR-ALPHA PROTEIN�EXPRESSION�AND�PRODUCTION�METHOD�THEREOF | December 2020 | November 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17133326 | CORNEAL ENDOTHELIAL CELL MARKER | December 2020 | April 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17131514 | APPARATUSES AND METHODS FOR PREPARING A COMESTIBLE MEAT PRODUCT | December 2020 | March 2022 | Allow | 15 | 3 | 0 | Yes | No |
| 17129708 | ADAM6 MICE | December 2020 | December 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 17129706 | ADAM6 MICE | December 2020 | September 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17114888 | REPROGRAMMING PROGENITOR COMPOSITIONS AND METHODS OF USE THEREOF | December 2020 | January 2024 | Allow | 37 | 2 | 0 | No | No |
| 17110446 | THREE DIMENSIONAL TISSUE PRINTING DEVICE, THREE DIMENSIONAL TISSUE PRINTING METHOD AND ARTIFICIAL SKIN | December 2020 | August 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17105156 | DIRECTED STEM CELL RECRUITMENT | November 2020 | June 2023 | Allow | 31 | 2 | 0 | No | No |
| 17056710 | SYSTEM OF CELL EXPANSION AND METHODS OF USING THE SAME | November 2020 | January 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17094350 | APPARATUS AND METHOD FOR LEVITATIONAL BIOFABRICATION OF ORGAN AND TISSUE ENGINEERED CONSTRUCTS USING TISSUE SPHEROIDS AND MAGNETOACOUSTIC BIFIELD | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17094327 | MESSENGER RNA THERAPY FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY | November 2020 | September 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 17081766 | RECOMBINANT ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF FRACTALKINE FOR TREATMENT OF NEUROINFLAMMATORY AND NEURODEGENERATIVE DISEASES | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17074481 | METHODS AND COMPOSITIONS FOR FEEDER-FREE PLURIPOTENT STEM CELL MEDIA CONTAINING HUMAN SERUM | October 2020 | June 2023 | Allow | 32 | 1 | 0 | No | No |
| 17071511 | TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS | October 2020 | September 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17071507 | TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17071627 | USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY | October 2020 | June 2024 | Allow | 44 | 2 | 0 | No | No |
| 17046264 | CELL STRUCTURE CONNECTION METHOD AND CONNECTION SUPPORT DEVICE | October 2020 | April 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17063139 | METHOD FOR DIFFERENTIATION INDUCTION IN CULTURED STEM CELLS | October 2020 | May 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17039784 | ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF | September 2020 | June 2025 | Abandon | 57 | 8 | 0 | Yes | No |
| 17039407 | BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES | September 2020 | June 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17039839 | RNA-Guided Endonuclease Expressing Algal Strain for High Efficiency In Vivo Genome Editing | September 2020 | March 2024 | Allow | 42 | 2 | 0 | No | No |
| 17042635 | CARDIOMYOCYTE MATURATION PROMOTER | September 2020 | February 2024 | Allow | 41 | 1 | 0 | No | No |
| 17014113 | PSORIASIS-INDUCED ANIMAL MODEL AND USE THEREOF | September 2020 | December 2023 | Abandon | 39 | 2 | 0 | No | No |
| 17010054 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | September 2020 | June 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 17001319 | MICROVESICLE AND METHOD FOR PRODUCING THE SAME | August 2020 | May 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16991758 | METHOD FOR RECONSTRUCTING IMMUNE FUNCTION USING PLURIPOTENT STEM CELLS | August 2020 | December 2023 | Allow | 40 | 2 | 0 | Yes | No |
| 16934503 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | July 2020 | April 2021 | Allow | 9 | 1 | 0 | No | No |
| 16913741 | METHOD TO BIOENGINEER DESIGNER RED BLOOD CELLS USING GENE EDITING AND STEM CELL METHODOLOGIES | June 2020 | December 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16958218 | SCAFFOLDING MATERIAL FOR STEM CELL CULTURES AND STEM CELL CULTURE METHOD USING SAME | June 2020 | April 2025 | Allow | 57 | 6 | 0 | Yes | No |
| 16908037 | Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof | June 2020 | July 2023 | Abandon | 37 | 2 | 0 | No | No |
| 16860519 | Functional Targeted Brain Endoskeletonization | April 2020 | October 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16846476 | SYSTEMS AND METHODS FOR ANGIOGENIC TREATMENT IN WOUND HEALING | April 2020 | May 2024 | Allow | 49 | 3 | 0 | No | No |
| 16840302 | HUMAN IPSC-BASED DRUG TESTING PLATFORM FOR MUSCULAR DYSTROPHY | April 2020 | July 2024 | Allow | 52 | 2 | 1 | Yes | Yes |
| 16836644 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | March 2020 | February 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 16834727 | Biosensors in Human Gut Organoids | March 2020 | November 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16831244 | ENHANCEMENT OF PRODUCTION OF NK CELLS FROM STEM CELLS | March 2020 | September 2022 | Allow | 29 | 4 | 1 | Yes | No |
| 16649475 | IN VITRO METHOD FOR PROVIDING STEM CELL DERIVED CARDIOMYOCYTES | March 2020 | May 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16648186 | FABRICATION OF A BIOMIMETIC PLATFORM SYSTEM AND METHODS OF USE | March 2020 | January 2025 | Abandon | 58 | 3 | 0 | No | No |
| 16820657 | METHODS AND COMPOSITIONS FOR PREPARING CARDIOMYOCYTES FROM STEM CELLS AND USE THEREOF | March 2020 | June 2024 | Abandon | 51 | 4 | 0 | No | No |
| 16809771 | NOVEL METHODS AND CULTURE MEDIA FOR CULTURING PLURIPOTENT STEM CELLS | March 2020 | January 2024 | Allow | 46 | 1 | 0 | No | No |
| 16639090 | A RELIABLE AND REPRODUCIBLE INDUSTRIALISATION PROCESS FOR THE ELIMINATION OF AIR BUBBLES IN THE PRODUCTION OF AN ENGINEERED VASCULAR TISSUE | February 2020 | February 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16751699 | AAV-VECTORS FOR USE IN GENE THERAPY OF CHOROIDEREMIA | January 2020 | October 2022 | Abandon | 33 | 0 | 1 | No | No |
| 16736802 | COMPOSITIONS AND METHODS FOR DETECTING CARDIOTOXICITY | January 2020 | March 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16727449 | RIBOFLAVIN DERIVATIVE-CONTAINING MEDIUM | December 2019 | January 2025 | Allow | 60 | 5 | 0 | Yes | No |
| 16719848 | METHOD OF MAKING A PERSONALIZED BONE GRAFT | December 2019 | May 2022 | Allow | 29 | 1 | 0 | No | No |
| 16624176 | MICROTISSUE COMPARTMENT DEVICE | December 2019 | September 2022 | Allow | 33 | 3 | 1 | Yes | No |
| 16713808 | GUT ORGANOID AND METHOD FOR PRODUCING THE SAME | December 2019 | December 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16712645 | Engineered Three-Dimensional Breast Tissue, Adipose Tissue, and Tumor Disease Model | December 2019 | May 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16708152 | BACTERIA CARRYING BACTERIOPHAGE AND PROTEASE INHIBITORS FOR THE TREATMENT OF DISORDERS AND METHODS OF TREATMENT | December 2019 | June 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16656452 | COMBINATORIAL CANCER IMMUNOTHERAPY | October 2019 | December 2020 | Allow | 14 | 1 | 1 | Yes | No |
| 16604973 | COMBINATORIAL CANCER IMMUNOTHERAPY | October 2019 | April 2022 | Allow | 30 | 3 | 1 | No | No |
| 16599732 | METHODS, DEVICES, AND COMPOSITIONS FOR MEASURING AND INDUCING CELL-TO-CELL COMMUNICATION, AND THERAPEUTIC USES THEREOF | October 2019 | October 2023 | Allow | 48 | 1 | 1 | Yes | No |
| 16595089 | BIOPROSTHETIC TISSUE HAVING A REDUCED PROPENSITY FOR IN VIVO CALCIFICATION | October 2019 | December 2021 | Allow | 26 | 1 | 0 | No | No |
| 16588864 | METHODS OF DIFFERENTIATING PREADIPOCYTES AND USES THEREOF | September 2019 | March 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16581150 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NETHERTON SYNDROME | September 2019 | December 2022 | Abandon | 38 | 6 | 0 | Yes | Yes |
| 16576803 | PRODUCTION OF CELLULAR SPHEROIDS | September 2019 | July 2024 | Allow | 58 | 2 | 1 | Yes | No |
| 16494249 | METHOD OF GENERATING 2 CELL-LIKE STEM CELLS | September 2019 | July 2023 | Abandon | 46 | 2 | 1 | No | No |
| 16562176 | CELL LINE, SYSTEM AND METHOD FOR OPTICAL-BASED SCREENING OF ION-CHANNEL MODULATORS | September 2019 | October 2021 | Abandon | 26 | 0 | 1 | No | No |
| 16490302 | METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES | August 2019 | April 2023 | Allow | 44 | 2 | 1 | Yes | No |
| 16486212 | CELL CULTURE METHOD AND CELL CULTURE SYSTEM | August 2019 | February 2025 | Allow | 60 | 7 | 0 | Yes | No |
| 16533830 | MAMMALIAN GENE MODIFICATION METHOD USING ELECTROPORATION | August 2019 | March 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16515155 | Engineered Liver Tissues, Arrays Thereof, and Methods of Making the Same | July 2019 | May 2021 | Allow | 22 | 2 | 0 | No | No |
| 16511612 | Use of Ion Concentrations to Increase the Packaging Efficiency of Recombinant Adeno-Associated Virus | July 2019 | August 2020 | Allow | 13 | 2 | 0 | Yes | No |
| 16510731 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | July 2019 | October 2021 | Allow | 27 | 2 | 0 | No | No |
| 16476564 | CRYOGEL 3D SCAFFOLDS AND METHODS FOR PRODUCING THEREOF | July 2019 | March 2023 | Allow | 44 | 1 | 0 | Yes | No |
| 16471312 | Composition for Promoting Proliferation of Pluripotent Stem Cells, and Method for Promoting Proliferation of Pluripotent Stem Cells | June 2019 | June 2023 | Allow | 48 | 4 | 0 | Yes | No |
| 16470584 | METHOD FOR EFFICIENTLY PRODUCING 3D MIDBRAIN-LIKE ORGANOID THROUGH SPECIFIC ELECTROMAGNETIC WAVE PROCESSING | June 2019 | February 2024 | Allow | 56 | 5 | 0 | No | No |
| 16435724 | ANTICANCER COMPOSITION COMPRISING RECOMBINANT ADENOVIRUS EXPRESSING DEGRADATION FACTOR FOR EXTRACELLULAR MATRIX | June 2019 | April 2025 | Abandon | 60 | 8 | 1 | Yes | No |
| 16466177 | USE OF PEPTIDE COMPOUNDS FOR PROMOTING SURVIVAL, GROWTH AND CELL DIFFERENTIATION | June 2019 | July 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16462753 | PERSONALIZED CELLULAR BIOMANUFACTURING WITH A CLOSED, MINIATURE CELL CULTURE SYSTEM | May 2019 | November 2022 | Abandon | 42 | 1 | 1 | No | No |
| 16404430 | System for Optical Stimulation of Target Cells | May 2019 | September 2020 | Abandon | 16 | 1 | 1 | No | No |
| 16345180 | GENETICALLY MODIFIED MOUSE MODEL FOR HUMAN HEPATOCYTE XENOTRANSPLANTATION | April 2019 | November 2023 | Abandon | 54 | 2 | 1 | No | No |
| 16341525 | COMPOSITIONS, CELL CONSTRUCTS, AND METHODS OF MAKING AND USING THE SAME | April 2019 | September 2023 | Allow | 53 | 4 | 1 | Yes | No |
| 16372358 | METHODS AND COMPOSITIONS FOR FEEDER-FREE PLURIPOTENT STEM CELL MEDIA CONTAINING HUMAN SERUM | April 2019 | February 2020 | Abandon | 10 | 1 | 0 | No | No |
| 16356570 | ORGAN REGENERATION METHOD UTILIZING BLASTOCYST COMPLEMENTATION | March 2019 | October 2021 | Abandon | 31 | 1 | 1 | No | No |
| 16356005 | SCALABLE LENTIVIRAL VECTOR PRODUCTION SYSTEM COMPATIBLE WITH INDUSTRIAL PHARMACEUTICAL APPLICATIONS | March 2019 | September 2021 | Abandon | 30 | 2 | 1 | No | Yes |
| 16331661 | METHOD AND APPARATUS FOR A TISSUE ENGINEERING SYSTEM | March 2019 | February 2021 | Allow | 24 | 0 | 1 | No | No |
| 16297070 | Preparation of artificial tissues by means of tissue engineering using fibrin and agarose biomaterials | March 2019 | August 2023 | Abandon | 54 | 3 | 0 | Yes | No |
| 16288809 | COMPOSITIONS CONTAINING AMNIOTIC COMPONENTS AND METHODS FOR PREPARATION AND USE THEREOF | February 2019 | January 2022 | Allow | 35 | 3 | 1 | Yes | No |
| 16288831 | Extracellular Matrix-Derived Gels and Related Methods | February 2019 | March 2022 | Abandon | 37 | 1 | 0 | No | No |
| 16278383 | ISOLATED PLACENTAL STEM CELL RECRUITING FACTORS | February 2019 | July 2022 | Allow | 41 | 2 | 0 | No | No |
| 16278415 | TARGETING DNA VACCINES TO B CELLS AS PRIMARY ANTIGEN PRESENTING CELLS | February 2019 | March 2021 | Abandon | 25 | 2 | 0 | No | No |
| 16322232 | BLOOD BRAIN BARRIER MODEL AND METHODS OF MAKING AND USING THE SAME | January 2019 | September 2021 | Allow | 31 | 2 | 1 | Yes | No |
| 16262442 | ONCOLYTIC EXPRESSION VECTOR COMPRISING A NUCLEIC ACID COMPRISING A NUCLEOTIDE SEQUENCE ENCODING GADD34 | January 2019 | November 2019 | Allow | 10 | 1 | 0 | No | No |
| 16258908 | METHOD OF GENE TRANSFER FOR THE TREATMENT OF RECESSIVE CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT) | January 2019 | July 2021 | Allow | 29 | 1 | 0 | No | No |
| 16256147 | NERVE TREATMENT DEVICES AND METHODS | January 2019 | August 2021 | Abandon | 31 | 1 | 0 | No | No |
| 16315687 | PSORIASIS-INDUCED ANIMAL MODEL AND USE THEREOF | January 2019 | December 2020 | Abandon | 23 | 2 | 1 | No | No |
| 16312772 | HEPATIC CELL LINE RESISTANT TO DIMETHYL SULFOXIDE, CELL CULTURE AND USES THEREOF | December 2018 | September 2022 | Abandon | 45 | 0 | 1 | No | No |
| 16311859 | ENGINEERED CARDIOMYOCYTES AND USES THREOF | December 2018 | May 2022 | Abandon | 41 | 0 | 1 | No | No |
| 16310632 | BIOLOGICALLY RELEVANT IN VITRO SCREENING OF HUMAN NEURONS | December 2018 | July 2022 | Abandon | 43 | 1 | 0 | No | No |
| 16304740 | NEOEPITOPE VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | November 2018 | May 2021 | Abandon | 29 | 3 | 1 | Yes | No |
| 16197194 | FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOF | November 2018 | March 2021 | Allow | 28 | 2 | 1 | Yes | No |
| 16194945 | Combinational use of mechanical manipulation and programin derivatives to increase Oct4, Sox2, Nanog or c-Myc expression in fibroblasts | November 2018 | April 2020 | Allow | 17 | 2 | 1 | Yes | No |
| 16177728 | COMPOSITION AND METHODS FOR CULTURING RETINAL PROGENITOR CELLS | November 2018 | June 2022 | Abandon | 44 | 1 | 0 | No | No |
| 16173875 | TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES | October 2018 | April 2022 | Allow | 41 | 2 | 0 | No | No |
| 16172364 | Metabolic Pressure for Stem Cell Differentiation and Purification | October 2018 | May 2022 | Abandon | 43 | 0 | 1 | No | No |
| 16096980 | ISL1-Based Gene Therapy to Treat Hearing Loss | October 2018 | March 2022 | Abandon | 41 | 4 | 1 | Yes | Yes |
| 16157930 | STEM CELL-DERIVED HEPATOCYTES IN CO-CULTURE AND USES THEREOF | October 2018 | April 2020 | Allow | 18 | 2 | 1 | Yes | No |
| 16092328 | IN VITRO MODEL FOR BLOOD-BRAIN BARRIER AND METHOD FOR PRODUCING IN VITRO MODEL FOR BLOOD-BRAIN BARRIER | October 2018 | June 2022 | Allow | 44 | 1 | 0 | No | No |
| 16091450 | ISOGENIC BLOOD-BRAIN BARRIER MODEL | October 2018 | August 2023 | Allow | 58 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOLOYE, TITILAYO.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MOLOYE, TITILAYO works in Art Unit 1632 and has examined 486 patent applications in our dataset. With an allowance rate of 60.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner MOLOYE, TITILAYO's allowance rate of 60.7% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MOLOYE, TITILAYO receive 2.86 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MOLOYE, TITILAYO is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +53.5% benefit to allowance rate for applications examined by MOLOYE, TITILAYO. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.4% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 39.9% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 71% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 81.6% of appeals filed. This is in the 74% percentile among all examiners. Of these withdrawals, 71.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 86.3% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.